行情

BPMX

BPMX

BIOPHARMX
AMEX

实时行情|Nasdaq Last Sale

0.2615
-0.0185
-6.61%
盘前: 0.2000 -0.0615 -23.52% 07:42 11/13 EST
开盘
0.2759
昨收
0.2800
最高
0.2759
最低
0.2580
成交量
26.98万
成交额
--
52周最高
4.675
52周最低
0.2580
市值
4,968.97万
市盈率(TTM)
-0.1579
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPMX 新闻

  • 阿里启动香港IPO!马云:逐步减少在蚂蚁金服经济利益
  • 新浪科技.26分钟前
  • 美股盘前:严阵以待鲍威尔证词 期指集体走弱
  • 新浪美股.31分钟前
  • 瑞幸咖啡Q3营收增5倍至15.42亿元 净亏损环比减少
  • 界面.34分钟前
  • 阿里启动香港IPO 软银实益拥有25.8%已发行在外股份
  • 新浪科技.46分钟前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

BPMX 简况

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.
展开

Webull提供Biopharmx Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。